Literature DB >> 12975406

QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure.

L Bode-Schnurbus1, D Böcker, M Block, R Gradaus, A Heinecke, G Breithardt, M Borggrefe.   

Abstract

BACKGROUND: Patients resuscitated from ventricular tachyarrhythmias benefit from implantable cardioverter-defibrillators (ICDs) as opposed to medical treatment. Patients with increased QRS duration receiving an ICD in the presence of heart failure are at greatest risk of cardiac death and benefit most from ICD therapy.
OBJECTIVE: To determine whether an increased QRS duration predicts cardiac mortality in ICD recipients.
DESIGN: Consecutive patients with heart failure in New York Heart Association functional class III were grouped according to QRS duration (< 150 ms, n = 139, group 1; v > or = 150 ms, n = 26, group 2) and followed up for (mean (SD)) 23 (20) months. PATIENTS: 165 patients were studied (80% men, 20% women); 73% had coronary artery disease and 18% had dilated cardiomyopathy. Their mean age was 62 (10) years and mean ejection fraction (EF) was 33 (14)%. They presented either with ventricular tachycardia (VT) or ventricular fibrillation (VF). MAIN OUTCOME MEASURES: Overall and cardiac mortality; recurrence rates of VT, fast VT, or VF.
RESULTS: Mean left ventricular EF did not differ between group 1 (33 (13)%) and group 2 (31 (15)%). Forty patients died (34 cardiac deaths). There was no difference in survival between patients with EF > 35% and < or = 35%. Cardiac mortality was significantly higher in group 2 than in group 1 (31.3% at 12 months and 46.6% at 24 months, v 9.5% at 12 months and 18.2% at 24 months, respectively; p = 0.04). The recurrence rate of VT was similar in both groups.
CONCLUSIONS: Within subgroups at highest risk of cardiac death, QRS duration-a simple non-invasive index-predicts outcome in ICD recipients in the presence of heart failure.

Entities:  

Mesh:

Year:  2003        PMID: 12975406      PMCID: PMC1767911          DOI: 10.1136/heart.89.10.1157

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  31 in total

1.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH).

Authors:  K H Kuck; R Cappato; J Siebels; R Rüppel
Journal:  Circulation       Date:  2000-08-15       Impact factor: 29.690

2.  [Significance of electrocardiography in the diagnosis and course observation of patients with congestive cardiomyopathy].

Authors:  H Kuhn; L K Breithardt; G Breithardt; L Seipel; F Loogen
Journal:  Z Kardiol       Date:  1974-10

3.  Prevalence and mortality rate of congestive heart failure in the United States.

Authors:  D D Schocken; M I Arrieta; P E Leaverton; E A Ross
Journal:  J Am Coll Cardiol       Date:  1992-08       Impact factor: 24.094

4.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; D Roy; R S Sheldon; L B Mitchell; M S Green; G J Klein; B O'Brien
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

5.  Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators.

Authors:  M J Domanski; S Sakseena; A E Epstein; A P Hallstrom; M A Brodsky; S Kim; S Lancaster; E Schron
Journal:  J Am Coll Cardiol       Date:  1999-10       Impact factor: 24.094

6.  Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study.

Authors:  R Sheldon; S Connolly; A Krahn; R Roberts; M Gent; M Gardner
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

7.  Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony.

Authors:  C L Grines; T M Bashore; H Boudoulas; S Olson; P Shafer; C F Wooley
Journal:  Circulation       Date:  1989-04       Impact factor: 29.690

8.  Serial electrocardiographic changes in idiopathic dilated cardiomyopathy confirmed at necropsy.

Authors:  R L Wilensky; P Yudelman; A I Cohen; R D Fletcher; J Atkinson; R Virmani; W C Roberts
Journal:  Am J Cardiol       Date:  1988-08-01       Impact factor: 2.778

9.  Effects of abnormal activation on the time course of the left ventricular pressure pulse in dilated cardiomyopathy.

Authors:  H B Xiao; S J Brecker; D G Gibson
Journal:  Br Heart J       Date:  1992-10

10.  Epidemiology of congestive heart failure.

Authors:  W M Smith
Journal:  Am J Cardiol       Date:  1985-01-11       Impact factor: 2.778

View more
  15 in total

1.  QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure.

Authors:  Tobias Breidthardt; Michael Christ; Miriam Matti; Delia Schrafl; Kirsten Laule; Markus Noveanu; Tujana Boldanova; Theresia Klima; Willibald Hochholzer; André P Perruchoud; Christian Mueller
Journal:  Heart       Date:  2007-03-29       Impact factor: 5.994

2.  Fragmented QRS in prediction of cardiac deaths and heart failure hospitalizations after myocardial infarction.

Authors:  Petri Korhonen; Terhi Husa; Teijo Konttila; Ilkka Tierala; Markku Mäkijärvi; Heikki Väänänen; Janne Ojanen; Aki Vehtari; Lauri Toivonen
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

3.  QRS width does not reflect ventricular dyssynchrony in patients with heart failure.

Authors:  Tomoe Uchiyama; Kazuo Matsumoto; Chikashi Suga; Ritsushi Kato; Shigeyuki Nishimura
Journal:  J Artif Organs       Date:  2005       Impact factor: 1.731

4.  [Echocardiographic evaluation to select patients for cardiac resynchronization therapy].

Authors:  A C Borges; F Knebel; S Eddicks; H-J Bondke; G Baumann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006

5.  Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II.

Authors:  Emily P Zeitler; Sana M Al-Khatib; Daniel J Friedman; Joo Yoon Han; Jeanne E Poole; Gust H Bardy; J Thomas Bigger; Alfred E Buxton; Arthur J Moss; Kerry L Lee; Paul Dorian; Riccardo Cappato; Alan H Kadish; Peter J Kudenchuk; Daniel B Mark; Lurdes Y T Inoue; Gillian D Sanders
Journal:  J Cardiovasc Electrophysiol       Date:  2017-08-23

6.  Lower body mass index and atrial fibrillation as independent predictors for mortality in patients with implantable cardioverter defibrillator.

Authors:  Christiana Schernthaner; Maximilian Pichler; Bernhard Strohmer
Journal:  Croat Med J       Date:  2007-02       Impact factor: 1.351

7.  Effects of Gender on Electrocardiography in Subjects with Shortened Ventricular Depolarization (QRS).

Authors:  Fatih Aydin; Meryem Aktoz; Armagan Altun; Erdal Gursul; Ercan Aksit
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-08-31       Impact factor: 1.468

8.  Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).

Authors:  Ritesh Dhar; Alawi A Alsheikh-Ali; N A Mark Estes; Arthur J Moss; Wojciech Zareba; James P Daubert; Henry Greenberg; Robert B Case; David M Kent
Journal:  Heart Rhythm       Date:  2008-02-16       Impact factor: 6.343

9.  Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN-HF Registry.

Authors:  Janice Y Chyou; Wan Ting Tay; Inder S Anand; Tiew-Hwa Katherine Teng; Jonathan J L Yap; Michael R MacDonald; Vijay Chopra; Seet Yoong Loh; Wataru Shimizu; Imran Zainal Abidin; Arthur Mark Richards; Javed Butler; Carolyn S P Lam
Journal:  J Am Heart Assoc       Date:  2021-03-13       Impact factor: 5.501

10.  Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation.

Authors:  Gül Erdemli; Albert M Kim; Haisong Ju; Clayton Springer; Robert C Penland; Peter K Hoffmann
Journal:  Front Pharmacol       Date:  2012-01-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.